scholarly journals Improving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agents

2014 ◽  
Vol 186 (7) ◽  
pp. 485-486
Author(s):  
J. N. Spaans ◽  
T. R. Asmis ◽  
G. G. Alvarez ◽  
G. D. Goss
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Targeted Agents ◽  
Northern Canada ◽  
Lung Cancer Treatment ◽  
Molecularly Targeted Agents

scholarly journals The Role of Surgery in Lung Cancer Treatment

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2777
Author(s):  
Francesco Petrella
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Lung Cancer Treatment

 [...]

scholarly journals Lung cancer treatment rates and the role of the lung cancer nurse specialist: a qualitative study

BMJ Open ◽  
2015 ◽  
Vol 5 (12) ◽  
pp. e008587 ◽  
Author(s):  
Angela Mary Tod ◽  
Judy Redman ◽  
Ann McDonnell ◽  
Diana Borthwick ◽  
John White
Keyword(s):  
Lung Cancer ◽  
Qualitative Study ◽  
Cancer Treatment ◽  
Nurse Specialist ◽  
Lung Cancer Treatment

Role of Genotyping in Non-Small Cell Lung Cancer Treatment

Drugs ◽  
2011 ◽  
Vol 71 (17) ◽  
pp. 2231-2246 ◽  
Author(s):  
Laura Bonanno ◽  
Adolfo Favaretto ◽  
Massimo Rugge ◽  
Miquel Taron ◽  
Rafael Rosell
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Treatment

Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review

2006 ◽  
Vol 24 (11) ◽  
pp. 1761-1769 ◽  
Author(s):  
Ping Yang ◽  
Jon O. Ebbert ◽  
Zhifu Sun ◽  
Richard M. Weinshilboum
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Treatment Outcome ◽  
Cancer Treatment ◽  
Metabolic Pathway ◽  
Drug Efficacy ◽  
Glutathione System ◽  
Lung Cancer Treatment ◽  
The Impact

Inherent and acquired drug resistance is a cause of chemotherapy failure, and pharmacogenomic studies have begun to define gene variations responsible for varied drug metabolism, which influences drug efficacy. Platinum-based compounds are the most commonly used chemotherapeutic agents in the treatment of advanced stage lung cancer patients, and the glutathione metabolic pathway is directly involved in the detoxification or inactivation of platinum drugs. Consequently, genotypes corresponding to higher drug inactivation enzyme activity may predict poor treatment outcome. Available evidence is consistent with this hypothesis, although a definitive role for glutathione system genes in lung cancer prognosis needs to be elucidated. We present evidence supporting a role of the glutathione system in acquired and inherited drug resistance and/or adverse effects through the impact of either drug detoxification or drug inactivation, thus adversely effecting lung cancer treatment outcome. The potential application of glutathione system polymorphic genetic markers in identifying patients who may respond favorably, selecting effective antitumor drugs, and balancing drug efficacy and toxicity are discussed.

scholarly journals An Overview of Lung Cancer in Women and the Impact of Estrogen in Lung Carcinogenesis and Lung Cancer Treatment

2021 ◽  
Vol 8 ◽  
Author(s):  
Vianey Rodriguez-Lara ◽  
Maria Rosa Avila-Costa
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Cancer Treatment ◽  
Critical Role ◽  
Lung Carcinogenesis ◽  
Lung Cancer Treatment ◽  
Incidence And Mortality ◽  
Menopausal Women ◽  
The Impact

Lung cancer incidence and mortality have significantly increased in women worldwide. Lung adenocarcinoma is the most common form of lung cancer globally. This type of lung cancer shows differences by sex, including the mutational burden, behavior, clinical characteristics, and response to treatment. The effect of sex on lung cancer patients' survival is still controversial; however, lung adenocarcinoma is considered a different disease in women and men. Moreover, lung adenocarcinoma is strongly influenced by estrogen and is also different depending on the hormonal status of the patient. Young pre-menopausal women have been explored as an independent group. They presented in more advanced stages at diagnosis, exhibited more aggressive tumors, and showed poor survival compared to men and post-menopausal women, supporting the role of sex hormones in this pathology. Several reports indicate the estrogen's role in lung carcinogenesis and tumor progression. Thus, there are currently some clinical trials testing the efficacy of antihormonal therapy in lung cancer treatment. This mini review shows the updated data about lung cancer in women, its characteristics, the etiological factors that influence carcinogenesis, and the critical role of estrogen in lung cancer and treatment.

The Role of Gefitinib in Lung Cancer Treatment

2004 ◽  
Vol 10 (12) ◽  
pp. 4233s-4237s ◽  
Author(s):  
Giuseppe Giaccone
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Lung Cancer Treatment
Sign in / Sign up

Export Citation Format

Share Document